Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Results Population characteristics The switching population included 854,054 patients
PMID 14576844
weight management for specific formulations like Saxenda and Wegovy) Healthcare professionals should remain vigilant for signs of pancreatitis, which is listed as a known adverse effect in the Summary of Product Characteristics (SmPC) for all GLP-1 agents There is no official link established between GLP-1 therapy and pancreatic cancer based on current evidence NICE guidance for type 2 diabetes management (NG28) continues to recommend GLP-1 receptor agonists as appropriate treatment options when specific criteria are met
The approval is based on research showing that 52 weeks of treatment with tirzepatide reduced study participants apnea or hypopnea events (losses of oxygen at night) compared to placebo
GLP1 agonist therapy may be used to address medically supervised weight reduction, obesity-related comorbidities, and longer-term weight management in appropriately evaluated patients
32.7% of participants taking 0.5mg and 36.4% of participants taking 1mg of Ozempic experienced gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea
